Introduction
The long-term outcomes in patients with inflammatory bowel diseases (IBD) can be optimised by adherence to preventive and monitoring protocols covering laboratory testing, endoscopic and imaging surveillance, and multidisciplinary management. Real-world adherence to currently proposed strategies among healthcare professionals and the availability of holistic services in an international context remain incompletely characterized.
Aims & Methods
The aim of this study was to evaluate the adherence to recommended strategies for patients with IBD and the access to holistic, multidisciplinary services . A cross-sectional, anonymous, international, voluntary online survey of clinicians who manage IBD patients was conducted . The 31-item questionnaire collected respondent demographics, practice setting and IBD patient volume, IBD experience, monitoring frequency in remission and active disease (clinical outcomes, biomarkers, IUS, MRI/CT, endoscopy), use of screening for anaemia and micronutrients.
Results
The survey included 171 healthcare professionals from 37 countries (strong European representation: Germany 22.8%, Poland 11.1%, Romania 6.4%, Spain and Italy 5.8% each). The cohort was gender-balanced (52.0% female), mainly general gastroenterologists (57.9%), with 14.0% IBD specialists and 8.2% internists; 70.8% were aged 31–45 . 43.9% had 1-5 years and 33.3% 5–15 years of IBD experience. Most worked in urban academic hospitals (61.4%). ECCO guideline adherence was high: follow-up in remission every 6 months was performed in 52.0% and at 3 months in 25.7% ; 88.3% performed biochemical monitoring (CRP, FCP) plus anaemia screening, and 84.2% screened at-risk patients for vitamin B12 and folate deficiency. Upper GI endoscopy in asymptomatic new IBD patients varied (always 40.4% ). Active-disease monitoring was mainly based on lab tests (92.4%) and endoscopy (80.1%); 79.5% used endoscopy to assess response to new therapies (timing: 12 weeks 36.3%, 1 year 33.3%, end of induction 14.0%). Decisions were commonly guided by STRIDE-II recommendations (70.8%). Biochemical remission defined intermediate control for 82.5% of responding physicians; clinical remission/ patient wellbeing 75.4%; QoL improvement 52.0%. Long-term remission assessment prioritized patient symptoms (80.7%), fecal calprotectin (FCP) (76.6%), and blood biomarkers (76.0%); endoscopy with biopsy for histologic remission was used by 70.8%, and QoL was formally assessed by 36.3%. IUS at diagnosis was used in 56.1%; during routine follow-up in 26.9%. 48.0% had regular Multidisciplinary Team (MDT) meetings for complex cases, but access to allied health professionals remained fragmented: 66.7% of respondents operated without access to a dedicated psychologist, 51.5% did not have support from dedicated IBD nurses, and 38.0 % had no access to a dietitian.
| Domain | Key finding, n (%) | Interpretation |
| Respondent profile | A total of 171 healthcare professionals from 37 countries participated; 61.4% were based in academic hospitals | International and predominantly academic sample |
| Preventive monitoring in remission | 151/171 (88.3%) reported routine biochemical monitoring and anemia screening in patients in remission; 144/171 (84.2%) screened at-risk patients for vitamin B12/folate deficiency | High adherence to guideline-recommended preventive monitoring |
| Monitoring of active disease | 158/171 (92.4%) used CRP/FCP and 137/171 (80.1%) used endoscopy to assess active disease; 136/171 (79.5%) performed endoscopic reassessment after treatment initiation | Monitoring strategies were largely aligned with treat-to-target principles |
| Treatment targets and decision-making | 121/171 (70.8%) reported that therapeutic decisions in suboptimal disease control were guided by STRIDE-II targets | Strong uptake of target-based management |
| Steroid-sparing practice | 103/171 (60.2%) intensified or modified treatment rather than prolonging corticosteroid exposure; 26/171 (15.2%) reported prolonged or repeated steroid use despite current therapy | Guideline-concordant steroid-sparing behaviour was common, although not universal |
| Intestinal ultrasound (IUS) | 96/171 (56.1%) used IUS at diagnosis; during follow-up, 46/171 (26.9%) used it routinely, 52/171 (30.4%) occasionally, and 69/171 (40.4%) never used it; the most commonly reported barrier was lack of experience/access (72/171, 42.1%) | IUS implementation remained limited and uneven |
| Multidisciplinary and holistic care | 88/171 (51.5%) reported no access to a dedicated IBD nurse, 114/171 (66.7%) no psychologist, and 65/171 (38.0%) no dietitian; regular MDT access was reported by 82/171 (48.0%) | Holistic and multidisciplinary support was inconsistent across centres |
Conclusion
This survey reports overall good adherence to established recommendations for monitoring and preventive care in patients with IBD. While the overall clinical monitoring strategies were convincing, the survey revealed structural gaps in holistic patient management, with limited access to allied health professionals such as psychologists, IBD nurses or dieticians
Disclosure
ETM: advisory board fee for MEdizin; Speaker fees from Johnson & Johnson, Sobi, Abbvie, Gilead. BG: advisory board fees from Abbvie, Pfizer, Alfasigma, MSD, Gilead and Roche. Speaker fees from Johnson & Johnson, Pfizer, Abbvie, Alfasigma, MD Education, Gilead, Roche, Takeda.
AD: reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Falk, Galapagos, J&J, Pfizer and Takeda; consultancy fees from AbbVie, Alfasigma, Amgen, J&J, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Sandoz, Stada, Takeda, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Alfasigma, CED Service GmbH, Celltrion, Falk, Fresenius Kabi, Ferring, Galapagos, Gilead, Hexal, High5MD, J&J, Materia Prima, MedToday, MSD, Pfizer, Sandoz, Streamed-Up, Takeda, and Vifor Pharma; payment for manuscript preparation from Abbvie, Falk, J & J, Takeda, Thieme, and UniMed Verlag. GR: Received lecture fees, consultancy fees from Takeda, Janssen, AbbVie, Celltrion, Pfizer, Bristol Myers Squibb, Ferring, Eli Lilly, Sanprobi, Pharmabest, Alfasigma, Bioton.The remaining authors declare none conflict of interest